315 related articles for article (PubMed ID: 22591422)
1. Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence.
Mulier S; Claes JP; Dierieck V; Amiel JO; Pahaut JP; Marcelis L; Bastin F; Vanderbeeken D; Finet C; Cran S; Velu T
Curr Pharm Des; 2012; 18(25):3793-803. PubMed ID: 22591422
[TBL] [Abstract][Full Text] [Related]
2. The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer.
Halkia E; Spiliotis J
J BUON; 2015 May; 20 Suppl 1():S12-28. PubMed ID: 26051328
[TBL] [Abstract][Full Text] [Related]
3. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
[No Abstract] [Full Text] [Related]
5. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial.
Deraco M; Kusamura S; Virzì S; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Iusco DR; Baratti D
Gynecol Oncol; 2011 Aug; 122(2):215-20. PubMed ID: 21665254
[TBL] [Abstract][Full Text] [Related]
6. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score.
Foster JM; Sleightholm R; Smith L; Ceelen W; Deraco M; Yildirim Y; Levine E; Muñoz-Casares C; Glehen O; Patel A; Esquivel J
J Surg Oncol; 2016 Dec; 114(7):779-784. PubMed ID: 27792292
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis.
Huo YR; Richards A; Liauw W; Morris DL
Eur J Surg Oncol; 2015 Dec; 41(12):1578-89. PubMed ID: 26453145
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
[TBL] [Abstract][Full Text] [Related]
9. Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
Bakrin N; Classe JM; Pomel C; Gouy S; Chene G; Glehen O
J Visc Surg; 2014 Oct; 151(5):347-53. PubMed ID: 25168575
[TBL] [Abstract][Full Text] [Related]
10. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.
Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P
Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512
[TBL] [Abstract][Full Text] [Related]
11. Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020).
Farrell R; Burling M; Lee YC; Pather S; Robledo K; Mercieca-Bebber R; Stockler M;
J Gynecol Oncol; 2022 Jan; 33(1):e1. PubMed ID: 34783204
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later?
Gonzalez Bayon L; Steiner MA; Vasquez Jimenez W; Asencio JM; Alvarez de Sierra P; Atahualpa Arenas F; Rodriguez del Campo J; Garcia Sabrido JL
Eur J Surg Oncol; 2013 Oct; 39(10):1109-15. PubMed ID: 23870278
[TBL] [Abstract][Full Text] [Related]
13. Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer.
Magge D; Ramalingam L; Shuai Y; Edwards RP; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL; Choudry HA
J Surg Oncol; 2017 Sep; 116(3):320-328. PubMed ID: 28628712
[TBL] [Abstract][Full Text] [Related]
14. An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer.
de Bree E; Michelakis D
Expert Opin Pharmacother; 2020 Aug; 21(12):1479-1492. PubMed ID: 32486865
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric ovarian tumors: a novel treatment approach.
Hayes-Jordan A; Lopez C; Green HL; Xiao LC; Huh W; Herzog CE
Pediatr Surg Int; 2016 Jan; 32(1):71-3. PubMed ID: 26500075
[TBL] [Abstract][Full Text] [Related]
16. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands.
Razenberg LG; van Gestel YR; Creemers GJ; Verwaal VJ; Lemmens VE; de Hingh IH
Eur J Surg Oncol; 2015 Apr; 41(4):466-71. PubMed ID: 25680955
[TBL] [Abstract][Full Text] [Related]
17. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
[TBL] [Abstract][Full Text] [Related]
18. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
[TBL] [Abstract][Full Text] [Related]
19. Residual tumour less than 0.25 centimetres and positive lymph nodes are risk factors for early relapse in recurrent ovarian peritoneal carcinomatosis treated with cytoreductive surgery, HIPEC and systemic chemotherapy.
Arjona-Sanchez A; Rufian-Peña S; Artiles M; Sánchez-Hidalgo JM; Casado-Adam Á; Cosano A; Thoelecke H; Ramnarine S; Garcilazo D; Briceño-Delgado J
Int J Hyperthermia; 2018 Aug; 34(5):570-577. PubMed ID: 29298538
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer.
Polom K; Roviello G; Generali D; Marano L; Petrioli R; Marsili S; Caputo E; Marrelli D; Roviello F
Int J Hyperthermia; 2016 May; 32(3):298-310. PubMed ID: 26984715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]